UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004119
Receipt number R000004952
Scientific Title Efficacy and safety of single-session endscopic ultrasonograpy guided fine needle aspiration biopsy and endscopic retrograde cholangiopancreatography for pathological diagnosis of pancreatic mass lesion.
Date of disclosure of the study information 2010/08/31
Last modified on 2010/08/27 22:58:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy and safety of single-session endscopic ultrasonograpy guided fine needle aspiration biopsy and endscopic retrograde cholangiopancreatography for pathological diagnosis of pancreatic mass lesion.

Acronym

Efficacy and safety of single-session EUS-FNAB and ERCP for pathological diagnosis of pancreatic mass lesion.

Scientific Title

Efficacy and safety of single-session endscopic ultrasonograpy guided fine needle aspiration biopsy and endscopic retrograde cholangiopancreatography for pathological diagnosis of pancreatic mass lesion.

Scientific Title:Acronym

Efficacy and safety of single-session EUS-FNAB and ERCP for pathological diagnosis of pancreatic mass lesion.

Region

Japan


Condition

Condition

pancreatic mass lesion

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

We prospectively evaluated the efficacy and safety of single-session EUS-FNA and ERCP. Accomplishment rate of procedure, time of procedure, and complication rate are evaluated.
We also study risk factors of single session EUS-FNAB and ERCP.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Accomplishment rate of procedure within 70 minutes

Key secondary outcomes

Accomplishment rate of procedure
Total time of procedure
Complication rate


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Maneuver

Interventions/Control_1

Single-session EUS-FNAB and ERCP is performed for sampling of pathological material to the patients with pancreatic mass lesion.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The study is designed to enroll the patients with suspicious pancreatic mass lesion on CT or US.

Key exclusion criteria

The exclusion criteria are as follows:
Karnofsky Performance Status <50%, active infection, the patient with inaccessible papilla Vater due to altered anatomy, Bleeding tendency(platelets<50000/mm3, prothrombin time<50%), severe complication such as liver cirrhosis and heart disease, active concomitant malignancy, and the patient inappropriate for entry onto this study under the judgment of the investigator.
Written informed consent is required from all patients.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hirofumi Kawamoto

Organization

Okayama University Hospital

Division name

Departments of Gastroenterology

Zip code


Address

2-5-1 Shikata-cho, Okayama 700-8558, Japan

TEL

086-223-7151

Email



Public contact

Name of contact person

1st name
Middle name
Last name Hirofumi Kawamoto

Organization

Okayama University Hospital

Division name

Departments of Gastroenterology

Zip code


Address

2-5-1 Shikata-cho, Okayama 700-8558, Japan

TEL

086-223-7151

Homepage URL


Email

h-kawamo@md.okayama-u.ac.jp


Sponsor or person

Institute

Okayama University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

岡山大学病院(岡山県)、倉敷中央病院(岡山県)、広島市民病院(広島県)


Other administrative information

Date of disclosure of the study information

2010 Year 08 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2009 Year 04 Month 28 Day

Date of IRB


Anticipated trial start date

2009 Year 06 Month 01 Day

Last follow-up date

2011 Year 09 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 08 Month 27 Day

Last modified on

2010 Year 08 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004952


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name